Aquestive Therapeutics, Inc. Common Stock (AQST) is a publicly traded Healthcare sector company. As of October 27, 2026, AQST trades at $4.06 with a market cap of $502.05M and a P/E ratio of -5.89. AQST moved +2.14% today. Year to date, AQST is -38.45%; over the trailing twelve months it is -41.96%. Its 52-week range spans $2.12 to $7.55. Analyst consensus is strong buy with an average price target of $8.67. Rallies surfaces AQST's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Aquestive’s Libervant deal brings $10 million upfront; Anaphylm review targets March 2027: Aquestive licensed Eton Pharmaceuticals exclusive US rights to Libervant for $10 million upfront, up to $47.5 million in milestones and mid-teens royalties; launch is expected in April 2027, subject to final approval. The FDA accepted Anaphylm’s resubmitted application with a March 16, 2027, goal date, and Aquestive plans a Canadian application in the fourth quarter of 2026.
| Metric | Value |
|---|---|
| Price | $4.06 |
| Market Cap | $502.05M |
| P/E Ratio | -5.89 |
| EPS | $-0.78 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.55 |
| 52-Week Low | $2.12 |
| Volume | 2.50K |
| Avg Volume | 0 |
| Revenue (TTM) | $44.55M |
| Net Income | $-83.78M |
| Gross Margin | 58.34% |
3 analysts cover AQST: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.67.